Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

28-05-2022 | Original Paper

Treatment of Attention-Deficit/Hyperactivity Disorder with Medication in Children with Autism Spectrum Disorder With and Without Intellectual Disability: A DBPNet Study

Auteurs: Joanna E. Grater, Elisa I. Muniz, Ellen J. Silver, Nathan J. Blum, Justine Shults, Ruth E. K. Stein

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 8/2023

Abstract

Children with autism spectrum disorder (ASD) and intellectual disability (ID)/global delay (GD) frequently have symptoms of attention-deficit/hyperactivity disorder (ADHD). We describe the practice patterns of developmental behavioral pediatricians (DBPs) in the treatment of children with ASD and coexisting ADHD and compare medication classes for children with and without intellectual disability. In bivariate analyses, we compared demographic characteristics, co-occurring conditions, and medication classes for children with and without intellectual disability. Significantly more patients with ID/GD were prescribed α-agonists than patients without ID/GD, but the difference was no longer significant when controlling for age in logistic regression children with ID/GD had more comorbidities and were more likely to be prescribed more than on psychotropic medication. In conclusion, age rather than ID/GD was associated with medication choice.

vorige artikel Sensory and Social Subtypes of Japanese Individuals with Autism Spectrum Disorders

volgende artikel A Systematic Review of Autistic People and the Criminal Justice System: An Update of King and Murphy (2014)

Aman, M. G., Buican, B., & Arnold, L. E. (2003). Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology, 13(1), 29–40.CrossRefPubMed

Aman, M. G., Kern, R. A., McGhee, D. E., & Arnold, L. E. (1993). Fenfluramine and methylphenidate in children with mental retardation and ADHD: Clinical and side effects. Journal of the American Academy of Child and Adolescent Psychiatry, 32(4), 851–859.CrossRefPubMed

Aman, M. G., Marks, R. E., Turbott, S. H., Wilsher, C. P., & Merry, S. N. (1991). Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. Journal of the American Academy of Child and Adolescent Psychiatry, 30(2), 246–256.CrossRefPubMed

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders. American Psychiatric Association.CrossRef

Barbaresi, W. J., Campbell, L., Diekroger, E. A., Froehlich, T. E., Liu, Y. H., O’Malley, E., Pelham, W. E., Jr., Power, T. J., Zinner, S. H., & Chan, E. (2020a). Society for developmental and behavioral pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder. Journal of Developmental and Behavioral Pediatrics, 41(Suppl 2S), S35–S57.CrossRefPubMed

Barbaresi, W. J., Campbell, L., Diekroger, E. A., Froehlich, T. E., Liu, Y. H., O’Malley, E., Pelham, W. E., Jr., Power, T. J., Zinner, S. H., & Chan, E. (2020b). The society for developmental and behavioral pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder: Process of care algorithms. Journal of Developmental and Behavioral Pediatrics, 41(Suppl 2S), S58–S74.CrossRefPubMed

Blum, N. J., Shults, J., Harstad, E., Wiley, S., Augustyn, M., Meinzen-Derr, J. K., Wolraich, M. L., & Barbaresi, W. J. (2018). Common use of stimulants and alpha-2 agonists to treat preschool attention-deficit hyperactivity disorder: A DBPNet study. Journal of Developmental and Behavioral Pediatrics, 39(7), 531–537.CrossRefPubMed

Christensen, D. L., Baio, J., Van Naarden Braun, K., Bilder, D., Charles, J., Constantino, J. N., Daniels, J., Durkin, M. S., Fitzgerald, R. T., Kurzius-Spencer, M., Lee, L. C., Pettygrove, S., Robinson, C., Schulz, E., Wells, C., Wingate, M. S., Zahorodny, W., & Yeargin-Allsopp, M. (2016). Centers for disease and prevention prevalence and characteristics of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 Sites, United States, 2012. MMWR Surveillance Summaries, 65(3), 1–23.CrossRefPubMedCentral

Fernandez-Jaen, A., Fernandez-Mayoralas, D. M., Calleja-Perez, B., Munoz-Jareno, N., Campos Diaz Mdel, R., & Lopez-Arribas, S. (2013). Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: A prospective, open-label study. Journal of Attention Disorders, 17(6), 497–505.CrossRefPubMed

Greenhill, L., Kollins, S., Abikoff, H., McCracken, J., Riddle, M., Swanson, J., McGough, J., Wigal, S., Wigal, T., Vitiello, B., Skrobala, A., Posner, K., Ghuman, J., Cunningham, C., Davies, M., Chuang, S., & Cooper, T. (2006). Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45(11), 1284–1293.CrossRefPubMed

Handen, B. L., Breaux, A. M., Janosky, J., McAuliffe, S., Feldman, H., & Gosling, A. (1992). Effects and noneffects of methylphenidate in children with mental retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 31(3), 455–461.CrossRefPubMed

Handen, B. L., Feldman, H., Gosling, A., Breaux, A. M., & McAuliffe, S. (1991). Adverse side effects of methylphenidate among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 30(2), 241–245.CrossRefPubMed

Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255.CrossRefPubMed

Handen, B. L., Sahl, R., & Hardan, A. Y. (2008). Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics, 29(4), 303–308.CrossRefPubMed

Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R. J., Escobar, R., Schacht, A., Pamulapati, S., Buitelaar, J. K., & Hoekstra, P. J. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51(7), 733–741.CrossRefPubMed

Harstad, E., Shults, J., Barbaresi, W., Bax, A., Cacia, J., Deavenport-Saman, A., Friedman, S., LaRosa, A., Loe, I. M., Mittal, S., Tulio, S., Vanderbilt, D., & Blum, N. J. (2021). Alpha2-adrenergic agonists or stimulants for preschool-age children with attention-deficit/hyperactivity disorder. JAMA, 325(20), 2067–2075.CrossRefPubMed

Jou, R. J., Handen, B. L., & Hardan, A. Y. (2005). Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15(2), 325–330.CrossRefPubMed

Mahajan, R., Bernal, M. P., Panzer, R., Whitaker, A., Roberts, W., Handen, B., Hardan, A., Anagnostou, E., & Veenstra-VanderWeele, J. (2012). Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders. Pediatrics, 130(Suppl 2), S125-138.CrossRefPubMed

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., … Psychopharmacolog, R. U. P. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321.CrossRefPubMed

Ming, X., Gordon, E., Kang, N., & Wagner, G. C. (2008). Use of clonidine in children with autism spectrum disorders. Brain and Development, 30(7), 454–460.CrossRefPubMed

Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 37(2), 367–373.CrossRefPubMed

Posey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006). Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 599–610.CrossRefPubMed

Rast, J. E., Anderson, K. A., Roux, A. M., & Shattuck, P. T. (2021). Medication use in youth with autism and attention-deficit/hyperactivity disorder. Academic Pediatric, 21(2), 272–279.CrossRef

Reichow, B., Volkmar, F. R., & Bloch, M. H. (2013). Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 43(10), 2435–2441.CrossRefPubMedPubMedCentral

Salazar, F., Baird, G., Chandler, S., Tseng, E., O’Sullivan, T., Howlin, P., Pickles, A., & Simonoff, E. (2015). Co-occurring psychiatric disorders in preschool and elementary school-aged children with autism spectrum disorder. Journal of Autism and Developmental Disorders, 45(8), 2283–2294.CrossRefPubMed

Scahill, L., J. T. McCracken, B. H. King, C. Rockhill, B. Shah, L. Politte, R. Sanders, M. Minjarez, J. Cowen, J. Mullett, C. Page, D. Ward, Y. Deng, S. Loo, J. Dziura, C. J. McDougle and N. Research Units on Pediatric Psychopharmacology Autism. (2015). Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. American Journal of Psychiatry, 172(12), 1197–1206.CrossRef

Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634-641.CrossRefPubMed

Simonoff, E., Taylor, E., Baird, G., Bernard, S., Chadwick, O., Liang, H., Whitwell, S., Riemer, K., Sharma, K., Sharma, S. P., Wood, N., Kelly, J., Golaszewski, A., Kennedy, J., Rodney, L., West, N., Walwyn, R., & Jichi, F. (2013). Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Journal of Child Psychology and Psychiatry, 54(5), 527–535.CrossRefPubMed

Stigler, K. A., Desmond, L. A., Posey, D. J., Wiegand, R. E., & McDougle, C. J. (2004). A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14(1), 49–56.CrossRefPubMed

Tarrant, N., Roy, M., Deb, S., Odedra, S., Retzer, A., & Roy, A. (2018). The effectiveness of methylphenidate in the management of attention deficit hyperactivity disorder (ADHD) in people with intellectual disabilities: A systematic review. Research in Developmental Disabilities, 83, 217–232.CrossRefPubMed

Wigal, T., Greenhill, L., Chuang, S., Mc, G. J., Vitiello, B., Skrobala, A., Swanson, J., Wigal, S., Abikoff, H., Kollins, S., Mc, C. J., Riddle, M., Posner, K., Ghuman, J., Davies, M., Thorp, B., & Stehli, A. (2006). Safety and tolerability of methylphenidate in preschool children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45(11), 1294–1303.CrossRefPubMed

Wolraich, M. L., Hagan, J. F., Jr., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., Zurhellen, W., & C,. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. https://doi.org/10.1542/peds.2019-2528CrossRefPubMed

Zeiner, P., Gjevik, E., & Weidle, B. (2011). Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatrica, 100(9), 1258–1261.CrossRefPubMed

Titel: Treatment of Attention-Deficit/Hyperactivity Disorder with Medication in Children with Autism Spectrum Disorder With and Without Intellectual Disability: A DBPNet Study
Auteurs: Joanna E. Grater
Elisa I. Muniz
Ellen J. Silver
Nathan J. Blum
Justine Shults
Ruth E. K. Stein
Publicatiedatum: 28-05-2022
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 8/2023
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-022-05611-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 8/2023

Shining a Light on a Hidden Population: Social Functioning and Mental Health in Women Reporting Autistic Traits But Lacking Diagnosis

Appropriateness, Acceptability, and Feasibility of a Neurodiversity-Based Self-determination Program for Autistic Adults

Impaired Biological Motion Processing and Motor Skills in Adults with Autistic Traits

Strong Relationship Between Rapid Auditory Processing and Affective Prosody Recognition Among Adults with High Autistic Traits

Sensory and Social Subtypes of Japanese Individuals with Autism Spectrum Disorders

Do Autism-Specific and General Developmental Screens Have Complementary Clinical Value?